



(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 9/00 (2006.01)
A61K 31/7052 (2006.01)

(21) International Application Number:

PCT/US2024/034183

(22) International Filing Date:

14 June 2024 (14.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/508,151 14 June 2023 (14.06.2023) US

(71) Applicant: **CHROMADEX INC.** [US/US]; 10900 Wilshire Blvd., Suite 600, Los Angeles, California 90024 (US).

(72) Inventors: **ERICKSON, Aron**; 1144 Gabriella Lane, Berthoud, Colorado 80513 (US). **REDPATH, Philip**; 10259 Echo Circle, Firestone, Colorado 80504 (US). **NKRUMAH-ELIE, Yasmee Maisha**; 21080 Lackland Place, Denver, Colorado 80249 (US). **SHAO, Andrew Earl**; 11140 Hazelnut Lane, Monrovia, Maryland 21770 (US).

(74) Agent: **CARRERA, JR., George M.** et al.; AMIN WASSERMAN GURNANI LLP, 230 W. Monroe Street, Suite 1405, Chicago, Illinois 60606 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF IN INTRAVENOUS FORMULATIONS AND METHODS OF USE THEREOF




FIG. 2A

(57) Abstract: A stable intravenous (I.V.) composition includes nicotinamide riboside (NR) as described, or other nicotinyl riboside compounds which are NAD⁺ precursors, in said intravenous form. NR chloride may be provided in an intravenous (I.V.) formulation for administration to a human subject.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

16 January 2025 (16.01.2025)